• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MG1141A 是一种针对 SARS-CoV-2 变体的高效单克隆中和抗体。

MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants.

机构信息

Department of Protein Engineering, Mogam Institute for Biomedical Research, Yongin, South Korea.

Department of Infectious Disease Research, Mogam Institute for Biomedical Research, Yongin, South Korea.

出版信息

Front Immunol. 2021 Nov 18;12:778829. doi: 10.3389/fimmu.2021.778829. eCollection 2021.

DOI:10.3389/fimmu.2021.778829
PMID:34868052
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8637776/
Abstract

Since the coronavirus disease outbreak in 2019, several antibody therapeutics have been developed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Antibody therapeutics are effective in neutralizing the virus and reducing hospitalization in patients with mild and moderate infections. These therapeutics target the spike protein of SARS-CoV-2; however, emerging mutations in this protein reduce their efficiency. In this study, we developed a universal SARS-CoV-2 neutralizing antibody. We generated a humanized monoclonal antibody, MG1141A, against the receptor-binding domain of the spike protein through traditional mouse immunization. We confirmed that MG1141A could effectively neutralize live viruses, with an EC of 92 pM, and that it exhibited effective Fc-mediated functions. Additionally, it retained its neutralizing activity against the alpha (UK), beta (South Africa), and gamma (Brazil) variants of SARS-CoV-2. Taken together, our study contributes to the development of a novel antibody therapeutic approach, which can effectively combat emerging SARS-CoV-2 mutations.

摘要

自 2019 年冠状病毒病爆发以来，已经开发出几种抗体疗法来治疗严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）感染。抗体疗法在中和病毒和减少轻度和中度感染患者的住院方面非常有效。这些疗法针对 SARS-CoV-2 的刺突蛋白；然而，该蛋白的新兴突变降低了它们的效率。在这项研究中，我们开发了一种通用的 SARS-CoV-2 中和抗体。我们通过传统的小鼠免疫产生了针对刺突蛋白受体结合域的人源化单克隆抗体 MG1141A。我们证实 MG1141A 可以有效中和活病毒，EC 为 92 pM，并且具有有效的 Fc 介导功能。此外，它保留了对 SARS-CoV-2 的 alpha（英国）、beta（南非）和 gamma（巴西）变体的中和活性。总之，我们的研究为开发一种新的抗体治疗方法做出了贡献，该方法可以有效对抗新兴的 SARS-CoV-2 突变。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76fc/8637776/efd09922ac6b/fimmu-12-778829-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76fc/8637776/1702b4590d48/fimmu-12-778829-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76fc/8637776/d109e3ff74c1/fimmu-12-778829-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76fc/8637776/34bd31c277ce/fimmu-12-778829-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76fc/8637776/4946ac2a9914/fimmu-12-778829-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76fc/8637776/efd09922ac6b/fimmu-12-778829-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76fc/8637776/1702b4590d48/fimmu-12-778829-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76fc/8637776/d109e3ff74c1/fimmu-12-778829-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76fc/8637776/34bd31c277ce/fimmu-12-778829-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76fc/8637776/4946ac2a9914/fimmu-12-778829-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76fc/8637776/efd09922ac6b/fimmu-12-778829-g005.jpg

相似文献

1
MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants.MG1141A 是一种针对 SARS-CoV-2 变体的高效单克隆中和抗体。
Front Immunol. 2021 Nov 18;12:778829. doi: 10.3389/fimmu.2021.778829. eCollection 2021.
2
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.人类针对 SARS-CoV-2 刺突蛋白受体结合域的中和抗体的结构基础。
Microbiol Spectr. 2021 Oct 31;9(2):e0135221. doi: 10.1128/Spectrum.01352-21. Epub 2021 Oct 13.
3
Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.MW06 是一种人源单克隆抗体，对 SARS-CoV-2 和 SARS-CoV 均具有交叉中和活性。
MAbs. 2021 Jan-Dec;13(1):1953683. doi: 10.1080/19420862.2021.1953683.
4
XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants.XAV-19，一种针对 SARS-CoV-2 刺突受体结合域的猪源糖基化人源化多克隆抗体，靶向多个表位并广泛中和变异株。
Front Immunol. 2021 Nov 15;12:761250. doi: 10.3389/fimmu.2021.761250. eCollection 2021.
5
Analysis of the molecular mechanism of SARS-CoV-2 antibodies.分析 SARS-CoV-2 抗体的分子机制。
Biochem Biophys Res Commun. 2021 Aug 20;566:45-52. doi: 10.1016/j.bbrc.2021.06.001. Epub 2021 Jun 5.
6
Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.结构分析 SARS-CoV-2 刺突蛋白的中和表位以指导治疗和疫苗设计策略。
Viruses. 2021 Jan 19;13(1):134. doi: 10.3390/v13010134.
7
Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.SARS-CoV-2 变异株对 COVID-19 恢复期患者体内诱导产生的抗体中和作用的抗性。
Cell Rep. 2021 Jul 13;36(2):109385. doi: 10.1016/j.celrep.2021.109385. Epub 2021 Jun 25.
8
The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants.抗 SARS-CoV-2 治疗性人源单克隆抗体对病毒变异体的中和效力保持不变。
Cell Rep. 2021 Sep 7;36(10):109679. doi: 10.1016/j.celrep.2021.109679. Epub 2021 Aug 21.
9
Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.针对 SARS-CoV-2 变体的广谱中和单克隆抗体的特性描述。
Viruses. 2022 Jan 24;14(2):230. doi: 10.3390/v14020230.
10
A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern and .一种基于双荧光的方法，用于鉴定针对 SARS-CoV-2 关切变异株和 的中和抗体。
J Virol. 2021 Oct 27;95(22):e0112621. doi: 10.1128/JVI.01126-21. Epub 2021 Sep 8.

引用本文的文献

1
Therapeutic Role of Neutralizing Antibody for the Treatment against SARS-CoV-2 and Its Emerging Variants: A Clinical and Pre-Clinical Perspective.中和抗体在治疗新冠病毒及其新变种中的作用：临床与临床前视角
Vaccines (Basel). 2022 Sep 26;10(10):1612. doi: 10.3390/vaccines10101612.
2
Collection of Monoclonal Antibodies Targeting SARS-CoV-2 Proteins.单克隆抗体针对 SARS-CoV-2 蛋白的收集。
Viruses. 2022 Feb 21;14(2):443. doi: 10.3390/v14020443.

本文引用的文献

1
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7.SARS-CoV-2 刺突缺失 H69/V70 的反复出现及其在 Alpha 变异株 B.1.1.7 中的作用。
Cell Rep. 2021 Jun 29;35(13):109292. doi: 10.1016/j.celrep.2021.109292. Epub 2021 Jun 8.
2
Structural Modeling of the SARS-CoV-2 Spike/Human ACE2 Complex Interface can Identify High-Affinity Variants Associated with Increased Transmissibility.SARS-CoV-2 刺突蛋白/人 ACE2 复合物界面的结构建模可以识别与传播性增加相关的高亲和力变体。
J Mol Biol. 2021 Jul 23;433(15):167051. doi: 10.1016/j.jmb.2021.167051. Epub 2021 May 14.
3
SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）逃脱了自然免疫，引发了关于疫苗和疗法的问题。
Nat Med. 2021 May;27(5):759-761. doi: 10.1038/s41591-021-01347-0.
4
Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization.SARS-CoV-2 变异株 P.1 对抗体中和的抵抗力增强。
Cell Host Microbe. 2021 May 12;29(5):747-751.e4. doi: 10.1016/j.chom.2021.04.007. Epub 2021 Apr 18.
5
Neutralizing monoclonal antibodies for treatment of COVID-19.用于治疗 COVID-19 的中和单克隆抗体。
Nat Rev Immunol. 2021 Jun;21(6):382-393. doi: 10.1038/s41577-021-00542-x. Epub 2021 Apr 19.
6
The SARS-CoV-2 Spike variant D614G favors an open conformational state.SARS-CoV-2 刺突变异株 D614G 有利于构象呈开放状态。
Sci Adv. 2021 Apr 16;7(16). doi: 10.1126/sciadv.abf3671. Print 2021 Apr.
7
A human coronavirus evolves antigenically to escape antibody immunity.一种人类冠状病毒会通过抗原进化来逃避抗体免疫。
PLoS Pathog. 2021 Apr 8;17(4):e1009453. doi: 10.1371/journal.ppat.1009453. eCollection 2021 Apr.
8
SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera.SARS-CoV-2 刺突变异株对恢复期或接种疫苗后的血清表现出不同的感染性和中和抗性。
Cell Host Microbe. 2021 Apr 14;29(4):522-528.e2. doi: 10.1016/j.chom.2021.03.008. Epub 2021 Mar 20.
9
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.恢复期血清和疫苗血清对 SARS-CoV-2 B.1.1.7 变异株的中和能力降低。
Cell. 2021 Apr 15;184(8):2201-2211.e7. doi: 10.1016/j.cell.2021.02.033. Epub 2021 Feb 18.
10
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.SARS-CoV-2 变体 B.1.351 从自然和疫苗诱导的血清中逃逸的证据。
Cell. 2021 Apr 29;184(9):2348-2361.e6. doi: 10.1016/j.cell.2021.02.037. Epub 2021 Feb 23.